Industry
Pharma & HCP
How patients and healthcare professionals decide: starting, switching and stopping treatments, what cost and coverage do to those decisions, and what doctors weigh that patients never see.
What do patients and prescribers actually do when the price, the risk or the evidence changes?
- #
48.5%
48.5% would stop the blood pressure pill once its copay rose from $15 to $60 a month, on top of no felt benefit and afternoon tiredness, up from 14.0% with the tiredness alone and 1.5% with no felt benefit alone. — Patient adherence breaks at the copay: 48.5% would stop a daily blood pressure pill when it jumps from $15 to $60 a month
base 200
- #
35%
35.0% would stay on an antidepressant that is helping at $150 a month, against 82.2% at $50 and 97.0% at $10; no clone rates itself more likely to stay on at a higher price. — Antidepressant cost: only 35.0% of US adults prescribed one for depression would stay on it at $150 a month, against 82.2% at $50
base 197
- #
82%
82% of US men are not open to getting a hair transplant, and none say they are very open — 82% of US men would not get a hair transplant, and 98% of those who see their hair thinning rule one out
base 200
- #
89%
89% give strong praise to Diet-and-Exercise Jordan, against 1% for Medication Jordan, who lost the same 60 pounds (separate samples) — 89% strongly praise weight lost through diet and exercise, against 1% when the same weight is lost on medication
base 200
- #
65.2%
65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine — Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep
base 198
Which questions does Brox answer in pharma & hcp?
What has Brox published on pharma & hcp?Newest first
-
Patient adherence breaks at the copay: 48.5% would stop a daily blood pressure pill when it jumps from $15 to $60 a month
48.5% 48.5% would stop the blood pressure pill once its copay rose from $15 to $60 a month, on top of no felt benefit and afternoon tiredness, up from 14.0% with the tiredness alone and 1.5% with no felt benefit alone. (base 200)
Read -
Antidepressant cost: only 35.0% of US adults prescribed one for depression would stay on it at $150 a month, against 82.2% at $50
35% 35.0% would stay on an antidepressant that is helping at $150 a month, against 82.2% at $50 and 97.0% at $10; no clone rates itself more likely to stay on at a higher price. (base 197)
Read -
82% of US men would not get a hair transplant, and 98% of those who see their hair thinning rule one out
82% 82% of US men are not open to getting a hair transplant, and none say they are very open (base 200)
Read -
89% strongly praise weight lost through diet and exercise, against 1% when the same weight is lost on medication
89% 89% give strong praise to Diet-and-Exercise Jordan, against 1% for Medication Jordan, who lost the same 60 pounds (separate samples) (base 200)
Read -
Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep
65.2% 65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine (base 198)
Read -
Patient out-of-pocket cost and prescribing: US physicians keep a preferred brand at $25 a month, split at $75, and 62.9% switch to a generic at $150
37.1% 37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises. (base 70)
Read -
After stopping a GLP-1, 67.5% keep the weight off by changing their diet on their own and 17.5% by fitness; a $29 maintenance program would draw 62.0%, a $149 one 19.3%
67.5% 67.5% of past GLP-1 users rely most on eating less or eating differently on their own to keep the weight off, and 17.5% on exercise or a fitness routine. (base 166)
Read -
AI summaries of a new drug's trial: 0 of 198 US physicians and other prescribers would rely on one with no sources, 55.1% when every number links to the paper and 72.7% once a named physician has checked it
55.1% 55.1% (109 of 198) would rely on an AI-generated one-page summary of a newly approved medicine's pivotal trial, a 5 or more of 7, when every number links to the exact line of the published paper it comes from, against 0 of 198 when it shows no sources and 72.7% (144 of 198) when a named independent physician has also checked it against the paper. (base 198)
Read -
New medicine launches: 72.9% of US physicians and other prescribers would try one in its first months when it is covered, 22.9% when patients pay $250 a month
22.9% 22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks. (base 70)
Read -
Pharma rep visits: 66.7% of US clinicians, mostly dermatologists, would turn away a rep who asks to come every two weeks, against 39.4% for a monthly visit
66.7% Asked by a rep for a medicine they already prescribe for a 10-minute in-person visit, 66.2% of US clinicians would agree to one every three months, 58.1% to one a month and 31.8% to one every two weeks; the share who would decline rises from 30.8% to 39.4% to 66.7%. (base 198)
Read -
Oral JAK inhibitor or biologic: 88.9% of US dermatologists start a pill-seeking eczema patient on the JAK, and only a $150 a month gap tips most to the biologic
88.9% For a healthy 35-year-old with moderate-to-severe eczema who dislikes injections and asks for a pill, 88.9% of US dermatologists would start an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month; 81.7% still would when the JAK costs $30 a month more, 69.0% at $75 more and 46.8% at $150 more. (base 126)
Read -
Switching a stable patient: 59% of US clinicians, mostly dermatologists, keep the current therapy at a 15-point efficacy gain, and a third still do at 30 points
58.6% 58.6% of US clinicians would keep a patient stable for two years on the current therapy when a newer one gets 75 patients in 100 to the treatment goal against 60, with similar safety and the same cost to the patient; 85.8% keep at 65 against 60 and 32.5% still keep at 90 against 60. (base 169)
Read -
New indication news: 73% of US clinicians, mostly dermatologists, would ignore the manufacturer's email first, and none would read more than three promotional emails a month
73.2% 73.2% of US clinicians would ignore the manufacturer's email first when a medicine they already prescribe gains a new indication, more than any other channel; nobody picked a colleague, a conference, or a journal as the one to ignore. (base 198)
Read -
Seeing it work keeps US adults on a statin they cannot feel: a cholesterol test result wins over 92.2% of those not yet certain, home delivery 27.5%, and a $30 a month rise is the top reason to stop below $50,000 a year
98% A follow-up blood test showing cholesterol down by a third lifts the share of US adults very likely to still be taking a daily statin a year later from 74.5% to 98.0%; automatic home delivery every three months at the same $10 a month lifts it to 80.5%. Every case had no side effects and no change in how the person feels. (base 200)
Read -
Only 2 of 173 US physicians discount pharmaceutical promotion because AI wrote it, while 63% discount content no expert has reviewed
2 Almost nobody objects to AI writing the content. They object to nobody checking it. (base 173)
Read -
Generic or brand? A $15 a month gap is enough for 89% of US clinicians, mostly dermatologists, to write the generic when a patient asks for the brand
88.9% 88.9% of US clinicians would prescribe the generic, after explaining the saving, when a patient asks for the brand and the brand costs the patient $15 a month more; at a $50 gap it is 98.5% and at $150 it is 99.0% (base 198)
Read -
Clinicians will recommend a health app alongside a medicine only when it costs the patient nothing: 96.3% would if it is covered, none at $30 a month
96.3% 96.3% of US healthcare professionals are likely to recommend an FDA-cleared app alongside a long-term medicine when insurance covers it and the patient pays $0; when it is not covered and the patient pays $30 a month none are likely to, and at $100 all 81 are very unlikely to (base 81)
Read -
Prior authorization, not the evidence, is what delays 14 of 18 US oncologists from prescribing a new first-line cancer regimen
14 14 of 18 US oncologists say prior authorization or coverage denials most often delay their first prescription of a newly approved first-line regimen; none named unfamiliar side effects or a formulary review. (base 18)
Read -
Dermatologists let the insurance plan pick between similar psoriasis biologics: 90.6% say the plan decides, and a $25 a month cost gap makes 86.3% very likely to switch
90.6% 90.6% of US dermatologists say that, between two psoriasis biologics with similar efficacy and safety, which one the patient's insurance plan prefers or approves with the least prior authorization decides which they start (base 117)
Read -
Insurance, not clinical doubt, is what holds back 66.1% of US dermatologists from moving moderate eczema patients off topicals and onto a systemic
66.1% 66.1% of US dermatologists say insurance requirements or prior authorization are what most often make them hold off moving an adult with moderate eczema from topicals to a systemic (base 127)
Read -
Side-effect fears hold back 67.0% of US adults from a recommended statin, and a test of their own heart risk, not a lower price, is what would change their minds
67% 67.0% say worry about side effects would most hold them back from starting a statin their doctor recommends while they feel well; 19.5% would rather try diet and exercise first and 2.5% name the monthly cost. (base 200)
Read -
When a plan drops GLP-1 weight-loss coverage, 65.5% of considerers turn away from medicine, not to cash, yet 80.6% would switch plans to keep it
65.5% 65.5% of GLP-1 considerers would turn to diet, exercise or a program (34.5%) or put treatment off (30.9%) if their plan dropped weight-loss coverage; 11.5% would pay a drug maker's cash price. (base 139)
Read -
Why past GLP-1 users stop, and what brings them back: side effects (35.3%) and cost (31.2%) lead, and the fix must match the reason, with 94.3% of cost quitters wanting coverage under $50 and 60.0% of side-effect quitters a lower dose
35.3% 35.3% of US past GLP-1 users say side effects were the main reason they stopped, and 31.2% the monthly cost or losing insurance coverage (base 170)
Read -
Cash to go ahead with a delayed $3,000 treatment: no US adult would for under $1,000, and 97 of 200 would need the full $3,000
0 There is no cheap nudge. Not one person in 200 would proceed for less than $1,000. (base 200)
Read
What do people ask about pharma & hcp?
- Why do patients stop taking a daily medicine after the first few months, and what would keep them on it?
- 48.5% of US adults who take a daily prescription medicine (n=200, November 2026) would stop a new blood pressure pill once its copay rose from $15 to $60 a month on top of no felt benefit and afternoon tiredness, against 14.0% before the copay rise and 1.5% with no side effect at all.Read the insight
- Why do US adults with depression stop an antidepressant, and what would have kept them on it?
- Cost and side effects: 82.2% of US adults prescribed an antidepressant for depression would stay on one that helps at $50 a month but 35.0% at $150, and 51.3% say a quick switch when side effects bother them would keep them on it (n=197, November 2026).Read the insight
- What do physicians want from a medical science liaison that a sales rep cannot give them?
- Real-world and subgroup evidence for patients like their own: 60.1% of US physicians and other prescribers on the Brox HCP panel name it as what they most want from a medical science liaison that a sales rep cannot give, and 65.2% rate a 20-minute liaison meeting at least moderately useful against 17.7% for a rep meeting (n=198, November 2026).Read the insight
- How much does a patient's out-of-pocket cost change what a physician is willing to prescribe?
- Between $25 and $75 a month: 4.3% of US physicians and other prescribers outside dermatology would pick a $5 generic over the brand-name medicine they prefer when the brand costs the patient $25 a month, 44.3% at $75 and 62.9% at $150 (n=70, November 2026).Read the insight
- After stopping a GLP-1, what do past users turn to for keeping the weight off: a diet program, fitness, supplements or nothing?
- In November 2026, 67.5% of US past GLP-1 users said they rely most on eating less or eating differently on their own to keep the weight off after stopping (n=166), against 17.5% on exercise, 12.0% on nothing in particular and 2.4% on a structured diet program.Read the insight
- Would a physician trust an AI summary of a new drug's trial data over the label or a rep?
- Over the rep but not the label: 55.1% of US physicians and other prescribers on the Brox panel would rely on an AI summary of a new medicine's pivotal trial when every number links to the published paper, none would rely on one with no sources, and 66.2% would ignore the sales rep first against 24.2% the AI summary and 0% the FDA label (n=198, November 2026).Read the insight
- What makes a physician try a newly launched medicine in its first six months: the trial data, a peer, the rep, or coverage?
- Coverage, more than trial data, decides it in practice: 72.9% of US prescribers outside dermatology are likely to prescribe a newly launched medicine with a clear phase 3 benefit in its first months when it is covered without prior authorization, 54.3% when prior authorization is needed and 22.9% when a patient pays $250 a month, even though 55.7% name trial data as their single biggest trigger (n=70, November 2026).Read the insight
- What makes a doctor stop seeing pharma reps altogether?
- Being asked too often, and their employer: 66.7% of US clinicians on the Brox HCP panel would decline a 10-minute pharma rep visit every two weeks against 39.4% monthly, and 24 of the 36 who no longer see reps name a practice or health system restriction (n=198, November 2026).Read the insight
- What makes a dermatologist choose a JAK inhibitor over a biologic, and what makes them avoid it?
- 88.9% of US dermatologists on the Brox panel would start a healthy 35-year-old with moderate-to-severe eczema who asks for a pill on an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month, falling to 81.7% at a $30 monthly gap, 69.0% at $75 and 46.8% at $150 (n=126, November 2026).Read the insight
- What does a physician need to see before switching a stable patient to a newer therapy, and how much better does it have to be?
- 58.6% of US clinicians on the Brox panel would keep a patient who has been stable for two years on their current therapy even when a newer one gets 15 more patients in 100 to the treatment goal at the same cost and with similar safety, and 32.5% would still keep them at 30 more (n=169, October 2026).Read the insight
Other industries
How should you read these findings?
Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.
Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.
What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.
Ask this of your own customers: humans@brox.ai